


Jumonji Domain-Containing Protein 4 (JMJD4) Antibody

Catalogue No.: abx025007



Covalent modification of histones plays critical role in regulating chromatin structure and transcription. While most covalent histone modifications are reversible, only recently has it been established that methyl groups are subject to enzymatic removal from histones. A family of novel JmjC domain-containing histone demethylation (JHDM) enzymes have been identified that perform this specific function. Histone demethylation by JHDM proteins requires cofactors Fe (II) and alpha-ketoglutarate. Family members include JHDM1 (demethylating histone 3 at lysine 36), and JHDM2A as well as JMJD2CH3K9 (both of which demethylate histone 3 at lysine 9). Contributions of histone demethylase activity to tumor development, decreases in cell proliferation, and hormone-dependent transcriptional activation have been observed.

Target:	Jumonji Domain-Containing Protein 4 (JMJD4)
Clonality:	Polyclonal
Reactivity:	Human
Tested Applications:	ELISA, WB
Host:	Rabbit
Recommended dilutions:	WB: 1/1000. Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated
Immunogen:	KLH-conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human JMJD4.
Isotype:	IgG
Form:	Liquid
Purification:	Purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Storage:	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

Datasheet

Version: 4.0.0

Revision date: 15 Jul 2025



UniProt Primary AC: Q9H9V9 ([UniProt](#), [ExPASy](#))

String: [9606.ENSP00000355720](#)

Molecular Weight: Calculated MW: 52.5 kDa

Buffer: PBS containing 0.09% sodium azide.

Note: THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

For Reference Only